[{"orgOrder":0,"company":"Brexogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"BRE-AD01","moa":"IL-31","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Brexogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Brexogen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Brexogen \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Brexogen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Biotech Showcase
                          Not Confirmed
                          Biotech Showcase
                          Not Confirmed

                          Details : BRE-AD01 is produced from stem cells (named 'BxC') stimulated with a specified, well-defined clinical available compound, which comprised the backbone of Brexogen's technology.

                          Brand Name : BRE-AD01

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          November 02, 2022

                          Lead Product(s) : BRE-AD01

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank